The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin
- PMID: 19536068
- DOI: 10.1038/clpt.2009.92
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin
Abstract
Organic cation transporters (OCTs) can mediate metformin transmembrane transport. We explored metformin pharmacokinetics in relation to genetic variations in OCT1, OCT2, OCT3, OCTN1, and MATE1 in 103 healthy male Caucasians. Renal clearance varied 3.8-fold and was significantly dependent on creatinine clearance (r(2) = 0.42, P < 0.0001), age (r(2) = 0.09, P = 0.002), and OCT1 polymorphisms. Carriers of zero, one, and two low-activity OCT1 alleles (Arg61Cys, Gly401Ser, 420del, or Gly465Arg) had mean renal clearances of 30.6, 33.1, and 37.1 l/h, respectively (P = 0.04, after adjustment for creatinine clearance and age). Immunohistochemical staining of human kidneys demonstrated OCT1 expression on the apical side of proximal and distal tubules. Increased renal clearance, in parallel with the known decreased hepatic uptake, may contribute to reduced metformin efficacy in low-activity genotypes. Renal OCT1 expression may be important not only in relation to metformin but with respect to other drugs as well.
Comment in
-
Current understanding of the pharmacogenomics of metformin.Clin Pharmacol Ther. 2009 Dec;86(6):595-8. doi: 10.1038/clpt.2009.144. Clin Pharmacol Ther. 2009. PMID: 19915604
Similar articles
-
Genetic and Epigenetic Regulation of Organic Cation Transporters.Handb Exp Pharmacol. 2021;266:81-100. doi: 10.1007/164_2021_450. Handb Exp Pharmacol. 2021. PMID: 33674913 Review.
-
A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin.Pharmacogenet Genomics. 2013 Oct;23(10):526-34. doi: 10.1097/FPC.0b013e328364a57d. Pharmacogenet Genomics. 2013. PMID: 23873119 Clinical Trial.
-
Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.AAPS J. 2013 Apr;15(2):571-80. doi: 10.1208/s12248-013-9460-z. Epub 2013 Feb 16. AAPS J. 2013. PMID: 23417334 Free PMC article.
-
Clinical pharmacokinetics of metformin.Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21241070 Review.
-
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.Hepatology. 2009 Oct;50(4):1227-40. doi: 10.1002/hep.23103. Hepatology. 2009. PMID: 19591196
Cited by
-
Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus.Acta Pharm Sin B. 2024 Feb;14(2):437-454. doi: 10.1016/j.apsb.2023.09.004. Epub 2023 Sep 15. Acta Pharm Sin B. 2024. PMID: 38322335 Free PMC article. Review.
-
The substrate and inhibitor binding mechanism of polyspecific transporter OAT1 revealed by high-resolution cryo-EM.Nat Struct Mol Biol. 2023 Nov;30(11):1794-1805. doi: 10.1038/s41594-023-01123-3. Epub 2023 Oct 16. Nat Struct Mol Biol. 2023. PMID: 37845412
-
Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review.Curr Diabetes Rev. 2024;20(4):e070823219470. doi: 10.2174/1573399820666230807145202. Curr Diabetes Rev. 2024. PMID: 37550919
-
Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers.J Pers Med. 2023 Mar 8;13(3):489. doi: 10.3390/jpm13030489. J Pers Med. 2023. PMID: 36983671 Free PMC article.
-
Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.Acta Pharm Sin B. 2023 Jan;13(1):1-28. doi: 10.1016/j.apsb.2022.08.018. Epub 2022 Aug 28. Acta Pharm Sin B. 2023. PMID: 36815037 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
